Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.

The pharmacogenomics journal - 1 Jul 2017

Tonk E C M, Gurwitz D, Maitland-van der Zee A-H, Janssens A C J W

Abstract excerpt

The progressing discovery of genetic variants associated with drug-related adverse events has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To further the use of pharmacogenetics in health care, tests with sufficient potential to improve efficacy and safety, as reflected by good clinical validity and population impact, need to be identified. The potential benefit of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dideoxynucleosides
Share to Drug Hypersensitivity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Genetic Testing

Share to Genetic Variation

Share to HLA-B Antigens

Share to Pharmacogenetics

Share to Simvastatin

Source

Open in PubMed Open full text

Identifiers

PMID: 27168098
DOI: 10.1038/tpj.2016.34
PMCID: PMC5549182

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.PMID 27168098Read ↗

Clinical Validity and Clinical Utility of Genetic TestsSemantic proximity Read ↗

Evaluating pharmacogenetic tests: a case example.Semantic proximity Read ↗

Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.Semantic proximity Read ↗

Computational variant predictors for pharmacogenomics: from evaluation of single alleles to assessment of adverse drug reactions to antidepressants.Semantic proximity Read ↗

Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.Semantic proximity Read ↗

Pharmacogenetics to predict drug-related adverse events.Semantic proximity Read ↗

Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkSemantic proximity Read ↗

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Semantic proximity Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.Semantic proximity Read ↗

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.